RxDoctor Payments Data

Mahdi Awwad, MD

Family Medicine · Plano, TXNPI 1023375995

Payments from drug & device makers

$34,024in general payments, 2019–2025

Across 76 payments — averaging $447.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$33K
  • Novo Nordisk$176
  • Merck$154
  • Medtronic$84
  • Amgen$64
  • Lilly USA, LLC$49
  • plus $112 from 5 others

What the payments were for

  • Speaking & faculty fees$32,82696%
  • Food & beverage$1,1984%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Organon54$33,385
Novo Nordisk4$176
Merck5$154
Medtronic1$84
Amgen3$64
Lilly USA, LLC3$49
Linus Health, Inc.2$33
Pfizer1$22
Astellas Pharma US Inc1$20
Exact Sciences1$20
Axsome Therapeutics, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,024 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$12,569
Medicare patients
30
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$28,930
MounjaroTirzepatide27$27,522
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$968
Gabapentin11$523
Albuterol Sulfate HfaAlbuterol Sulfate19$488
Levothyroxine Sodium24$246
Morphine Sulfate12$222
Omeprazole12$212
Zolpidem Tartrate17$151
Amlodipine Besylate20$150
Pantoprazole Sodium18$145
Triamcinolone Acetonide14$131
Atorvastatin Calcium25$128
Escitalopram Oxalate12$95
Losartan Potassium14$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$176$28,93027 claims
Lilly USA, LLCMounjaro$49$27,52227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →